



HHS Public Access

Author manuscript

Int J Cancer. Author manuscript; available in PMC 2018 January 18.

Published in final edited form as:

Int J Cancer. 2017 July 15; 141(2): 254–263. doi:10.1002/ijc.30724.

Metformin Use and Survival after Non-Small Cell Lung Cancer: A Cohort Study in the U.S. Military Health System

Jie Lin^{1,*}, Abigail Gill¹, Shelia H. Zahm², Corey A. Carter¹, Craig D. Shriver^{1,3}, Joel A. Nations¹, William F. Anderson², Katherine A. McGlynn², and Kangmin Zhu^{1,4,*}

¹John P. Murtha Cancer Center, Walter Reed National Military Medical Center, Bethesda, MD

²Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

³Department of Surgery, Uniformed Services University of Health Sciences, Bethesda, MD

⁴Department of Preventive Medicine and Biostatistics, Uniformed Services University of Health Sciences, Bethesda, MD

Abstract

Research suggests that metformin may be associated with improved survival in cancer patients with type II diabetes. This study assessed whether metformin use after non-small cell lung cancer (NSCLC) diagnosis is associated with overall survival among type II diabetic patients with NSCLC in the U.S. military health system (MHS). The study included 636 diabetic patients with histologically confirmed NSCLC diagnosed between 2002 and 2007, identified from the linked database from the Department of Defense's Central Cancer Registry (CCR) and the Military Health System Data Repository (MDR). Time-dependent multivariate Cox proportional hazards models were used to assess the association between metformin use and overall survival during follow up. Among the 636 patients, 411 died during the follow up. The median follow up time was 14.6 months. Increased post-diagnosis cumulative use (per one-year of use) conferred a significant reduction in mortality (adjusted hazard ratio (HR)=0.76; 95% CI=0.65 to 0.88). Further analysis by duration of use revealed that compared to non-users, the lowest risk reduction occurred among patients with the longest duration of use (i.e. use for more than 2 years) (HR=0.19; 95% CI=0.09 to 0.40). Finally, the reduced mortality was particularly observed only among patients who also used metformin before lung cancer diagnosis and among patients at early stage of diagnosis. Prolonged duration of metformin use in the study population was associated with improved survival, especially among early stage patients. Future research with a larger number of patients is warranted.

*Correspondence to: Jie Lin, PhD, MPH or Kangmin Zhu, MD, PhD, Division of Military Epidemiology and Population Sciences, John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 11300 Rockville Pike, Suite 1120, Rockville, MD 20852; Phone: 301-816-4787 (Dr. Lin), 301-816-4786 (Dr. Zhu) jlin@murthacancercenter.org (Dr. Lin), or kzhu@murthacancercenter.org (Dr. Zhu).

Disclaimers: The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Army, Department of Defense (DoD), National Cancer Institute, nor the U.S. Government. Nothing in the presentation implies any Federal/DoD endorsement.

Disclosure: This project was supported by John P. Murtha Cancer Center, Walter Reed National Military Medical Center via the Uniformed Services University of the Health Sciences under the auspices of the Henry M. Jackson Foundation for the Advancement of Military Medicine and by the intramural research program of the National Cancer Institute. The original data linkage was supported by the United States Military Cancer Institute and Division of Cancer Epidemiology and Genetics, National Cancer Institute. The authors declare no conflicts of interest or financial disclosures.

Keywords

Metformin; survival; non-small cell lung cancer; Type II diabetes

Introduction

Diabetes is a common chronic disease that affects approximately 8.3% of the U.S. population, with type II diabetes accounting for 95% of the disease¹. As one of the most prevalent chronic diseases in US, type II diabetes coexists with cancer in nearly 20% of cancer patients². Type II diabetes is characterized by insulin resistance and compensatory hyperinsulinemia. Elevated insulin levels due to insulin resistance have been shown to promote tumor proliferation, increase cancer progression, and worsen clinical outcome³. Metformin is a glucose-lowering oral medication commonly prescribed as the first-line treatment of non-insulin dependent type II diabetes⁴. Metformin increases insulin sensitivity and lowers circulating insulin levels by activating AMP-activated protein kinase (AMK), leading to decreased hepatic gluconeogenesis⁵. Metformin has multiple anticancer mechanisms⁶, including the induction of apoptosis⁷, a direct down-regulation of tumor proliferating kinases⁸ and an indirect benefit of reducing circulating glucose and insulin levels⁹. There is epidemiologic evidence that metformin may be associated with decreased cancer incidence¹⁰. A recent review and meta-analysis reported a 31% reduction in cancer incidence among metformin users, while some methodological issues remained¹¹.

The potential role of metformin in regulation of cellular energy metabolism, apoptosis and tumor proliferation has attracted much attention to its effects on cancer outcomes after diagnosis^{11, 12}. The association between metformin use and survival among cancer patients has been studied but the results are not as consistent as those on cancer incidence. While favorable survival outcomes associated with metformin use have been found in patients with breast cancer^{13, 14}, colon cancer^{15, 16}, prostate cancer¹⁷, and other cancers^{18, 19} meta-analyses have suggested interpretation with caution due to methodological bias (e.g. immortal time bias) and inadequate control for confounding in some studies^{11, 12}.

Lung cancer is the leading cause of cancer-related deaths worldwide²⁰. Non-small cell lung cancer (NSCLC) comprises about 85% to 90% of all lung cancers²⁰. Type II diabetes is a common comorbidity among lung cancer patients, which has been shown to increase the mortality among lung cancer patients^{21, 22}. Based on research on other cancers^{13–15, 17} and biological plausibility^{23, 24}, we hypothesize that metformin use may also be associated with better survival among lung cancer patients with type II diabetes. There are few studies on the relationship between metformin use and survival among NSCLC patients with Type II diabetes^{25–30} and the results showed survival benefit^{25, 27, 28, 30}, no association²⁹ or worse survival²⁶. Among observational investigations, a recent study based on the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)-Medicare database reported 20% mortality reduction associated with metformin use among stage IV NSCLC patients²⁸, while an earlier study based on medical records from the Cleveland Clinic Health System found increased risk of mortality among users²⁶. Results from clinical trials are also inconsistent, supporting either a survival benefit²⁷ or no effects²⁹. A recent lung cancer

study, which did not differentiate NSCLC or small cell lung cancer, reported a weak non-significant reduction in lung-cancer specific mortality³¹. The differences in study design, timing of metformin use, characteristics of patient population, and variations in cancer treatment and data sources may have influenced the study results.

The U.S. Military Health System provides universal care to its beneficiaries and therefore, the potential effects of different levels of access to care, which are related to racial disparity in diabetes care^{32, 33}, the use of treatment and cancer outcomes, may be minimized for a study on metformin and survival. Using the linked data from the Department of Defense (DoD) Central Cancer Registry (CCR) and the Military Health System (MHS) Data Repository (MDR), we assessed whether metformin use after NSCLC diagnosis is associated with overall survival in NSCLC patients with type II diabetes.

Materials and Methods

Data source

This study was based on the MHS, which provides health care to active duty members, retirees, National Guard and Reserve members, and their dependents. The linked database from the CCR and MDR, described previously³⁴, served as the data source of this study. The CCR contains data on demographics, cancer diagnosis, tumor characteristics, cancer treatment, and vital status from the records of cancer patients diagnosed and/or treated at military treatment facilities (MTFs). Cancer site and histology codes are based on the International Classification of Diseases for Oncology, third edition (ICD-O-3)³⁵, in the CCR data. The registry staff conduct lifetime follow-up on patients. The CCR registrars follow up with patients and review medical records to identify vital status. The Defense Manpower Data Center (DMDC) data and obituary listings are also used for this purpose. Both CCR and MDR data in the linked database cover the period from 1998 to 2007. The MDR contains administrative and medical claims data from in-patient and out-patient services provided directly at MTFs (direct care) or paid for by the DoD at civilian facilities (indirect care). The MDR database includes information on clinical diagnoses of all medical conditions, which are coded using the International Classification of Disease, 9th Revision (ICD-9), and diagnostic and treatment procedures, which are coded using ICD-9 or Current Procedural Terminology (CPT) codes. The MDR pharmacy dataset contains pharmacy records for all sources of care provided by military treatment facility, mail order, or retail. The pharmacy data are available from year 2002 and on.

The data linkage project was reviewed and approved by the institutional review boards of the Walter Reed National Military Medical Center, Tricare Management Activity, and the National Institutes of Health Office of Human Subjects Research.

Study subjects

Study subjects were patients with histologically-confirmed- primary malignant NSCLC diagnosed between 2002 (the year when MDR pharmacy data became available) and 2007 and identified from CCR that includes cancer patients diagnosed and/or treated at MTFs. Patients also had type II diabetes diagnosed before or at the time of NSCLC diagnosis. The

study subjects were identified from the linked CCR and MDR database. Cancer site and histology were classified using the topography (C34.0 to C34.3, C34.8, C34.9) and morphology codes (8050-8078, 8083, 8084, 8250-8260, 8480-8490, 8570-8574, 8140, 8211, 8230, 8231, 8323, 8550, 8551, 8576, 8010-8012, 8014-8031, 8035, 8310) of the ICD-O-3³⁵. Type II diabetes was ascertained from the MDR using ICD-9 diagnostic codes (250.x0, 250.x2, 357.2, 362.00-362.02, and 366.41), with the requirement that patients had the diagnosis in at least one inpatient record or three outpatient records³⁶. Three outpatient records were used to reduce false diagnosis.

Metformin use and survival

The baseline was defined as the date of NSCLC diagnosis. The study outcome was all-cause death during follow up. The study end point was date of death, date of last contact, or the study end date, i.e. December 31, 2009. Survival times for subjects who did not die during follow-up were censored at the study end date. We used proprietary and non-proprietary names recorded in the MDR's pharmacy database to identify prescriptions for metformin. We used two variables to measure post-diagnostic metformin use: ever use (yes or no) and cumulative duration of use. Ever use was defined as "yes" if there was at least one record indicating that the medication was prescribed after diagnosis. Cumulative duration of use was the sum of the mandatory days of supply of each prescription over time during follow up. Considering the potential impact of immortal time bias³⁷, in which exposure (metformin use) occurs after baseline and only those who survive to the point of exposure could have the chance to be exposed, therefore biasing the results towards a beneficial drug effect time, we analyzed the exposure variables as time-dependent variables (see statistical analysis below). Metformin use before NSCLC diagnosis was analyzed as a conventional time-fixed variable in the analysis.

Other variables

This study also included variables of NSCLC tumor stage, grade, cancer treatments, comorbidity index, tobacco use, and demographic characteristics. Tumor stage and grade were obtained from CCR. Tumor stage was in accordance of the American Joint Committee on Cancer (AJCC) staging system³⁸. Stage was further grouped into early stage (stages I and II)³⁹, and late stage (stages III and IV)⁴⁰. Data on the receipt of cancer surgery, chemotherapy, and radiation therapy were from both MDR and CCR and consolidated. Comorbidities were obtained from the MDR. A comorbid condition was considered to be present if at least one inpatient record or three outpatient records^{41, 42} showed the diagnosis prior to the NSCLC diagnosis. The level of comorbidity was categorized according to the Charlson comorbidity index⁴³ with lung cancer diagnosis and type II diabetes diagnosis excluded. The index score was further grouped into three groups with index score of 0, 1 and 2 or more, respectively. Tobacco use (never, former and current use) and demographic characteristics were available in CCR. Similar to metformin use, use of other anti-diabetic medications, such as insulin, insulin secretagogues (i.e. a group of drugs including sulfonylureas) and aspirin, was extracted from the MDR pharmacy database.

Statistical analysis

As mentioned, the study end point was death, date of last contact, or the study end date, i.e. December 31, 2009. Differences in characteristics by post-diagnostic user status were compared and tested using Chi-square test. The effect of post-diagnosis use (yes vs. no) and risk of all-cause mortality was analyzed in time-dependent Cox regression model. Post-diagnosis cumulative duration of use in relation to the risk of all-cause mortality was also modeled as a time-dependent variable in Cox proportional hazard models. This variable was a continuous variable with unit in days. Since the clinical effect of single day use is negligible, we assessed the effects of post-diagnostic cumulative use based on year of use. We then categorized cumulative use into three groups (>0 to 12 months, > 12 to 24 months and > 24 months) and investigated the effects of each duration group compared to no use as the reference group.

In all models, hazard ratios (HRs) and 95% confidence interval (95% CI) were estimated, adjusting for confounding variables that were related to both metformin use and survival, including tumor stage (stages I, II, III and IV); cancer treatments (yes or no); tobacco use (no use, previous use, current use and unknown); comorbidity index groups (0, 1, 2 or more); age, sex (male, female), race (White, Black, Asian, Other and unknown); baseline use of metformin (yes, no), insulin and insulin secretagogues (yes, no), baseline aspirin use (yes, no) and years in cohort. Baseline use of anti-diabetic drugs was defined as the use before NSCLC diagnosis. The effect of cumulative post-diagnostic duration on all-cause mortality was also stratified by metformin use at baseline and tumor stage.

Statistical Analysis System (SAS) software, Version 9.3 for Windows (SAS Institute, Inc., Cary, North Carolina) was used to perform statistical analyses. All tests of significance were two-tailed and performed at an alpha of 0.05.

Results

The study included a cohort of 636 NSCLC patients with type II diabetes. The median time from diagnosis of Type II diabetes to NSCLC diagnosis was 72 months. As this is a cohort of diabetic patients with NSCLC, some patients had already taken metformin and/or other diabetic medications at baseline. The median time of metformin use at baseline was 20.65 months. During follow up, among the 636 patients, 259 patients used metformin, while 377 patients did not use.

Table 1 showed characteristics of the study population by post-diagnostic metformin user groups. Due to the low number of subjects who used more than 24 months, this group was combined with the group of >12 and 24 months in this table. Overall, non-users, short-term users (use 12 months or shorter) and long-term users (use more than 12 months) were significantly different by age ($P=0.016$), sponsor service branch ($P=0.019$), comorbidity index group ($P=0.002$), tumor stage ($P<0.001$), baseline metformin use ($P<0.001$), insulin secretagogues use ($P<0.001$) and aspirin use ($P<0.001$). Short-term and long-term users were similar in the distribution of age, comorbidity, baseline metformin use, baseline insulin secretagogues use, and baseline aspirin use, but both groups were different from non-users by these variables. For example, compared to non-users, both short term users and long term

users were younger, had less comorbidity, more likely to use metformin, insulin secretagogues and aspirin at baseline. However, compared to long-term users, short term users were more likely to be diagnosed at advanced stage.

During the follow up period (median follow up time of 14.6 months), 411 patients died. The time-dependent Cox model using post-diagnostic metformin use (yes vs. no) as the exposure variable did not show significant association between the use and all-cause mortality after adjusting for age, sex, race, tobacco use, comorbidity, cancer stage, histology, receipt of treatments, baseline use of metformin, insulin, insulin secretagogue, aspirin and years in the cohort (HR=1.27, 95% CI=0.94 to 1.72) (Data not shown). However, post-diagnostic cumulative metformin use, modeled as per one-year of use during follow up, was associated with a 24% reduction in all-cause mortality (HR=0.76, 95% CI=0.65 to 0.88) in time-dependent Cox model, after adjusting for the same set of covariates (Table 2).

Further analysis by duration groups showed that compared to non-users, there was an initial increased mortality risk during the first year of use (HR=2.05, 95% CI=1.51 to 2.78), and then the risk declined as the duration of use increased, with the most risk reduction observed in the patients who used metformin for the longest period of time (more than 24 months) (HR=0.19, 95% CI=0.09 to 0.40), respectively (Table 3).

We further stratified the analysis of cumulative duration of post-diagnostic use by metformin use before NSCLC diagnosis. As shown in Table 4, cumulative use (per one-year of use) during follow up was associated with a significant reduction in mortality (HR=0.68, 95% CI=0.57 to 0.82) only among those who used metformin before NSCLC diagnosis, while there was no association among those who did not use metformin before diagnosis (HR=0.99, 95% CI=0.78 to 1.25) (Table 4). Similarly, in cumulative group analysis, significant risk reduction conferred by the longest duration of use (more than 24 months) was only observed among patients who used metformin before cancer diagnosis (HR=0.13, 95% CI=0.06 to 0.29), but not in those who did not use metformin before cancer diagnosis (HR=0.80, 95% CI=0.31 to 2.10) (Table 4).

We finally stratified the analysis by tumor stage groups. As shown in Table 5, cumulative use (per one-year of use) during follow up conferred a non-significant reduction in mortality (HR=0.84, 95% CI=0.66 to 1.06) among early stage patients, but not among late stage patients (HR=0.92, 95% CI=0.78 to 1.10) (Table 5). Among early stage patients, HR first increased for 12 month and then reduced with the most reduction in mortality occurred among those who used for the longest period of time (HR=0.26, 95% CI=0.09 to 0.73) (Table 5).

Discussion

Our study in the U.S. military health system showed that ever use of metformin (yes vs. no) after NSCLC diagnosis was not associated with all-cause mortality during follow up in the study population. However, cumulative use (modeled as per one-year of use) after diagnosis was associated with an overall significant reduction in mortality. When analyzed by specific duration of use, there was an initial increase of mortality associated with the first twelve

months of use, followed by continued risk reduction with the highest reduction occurred among patients with the longest duration of use (i.e. use for more than 2 years). Finally, the reduced mortality conferred by a long cumulative duration was only observed among patients who also used metformin before cancer diagnosis, suggesting that the beneficial effect was apparent with prolonged use, and it may be particularly true for those with early-stage tumors.

There have been a few studies examining metformin use and survival among lung cancer patients^{25–31}. However, the results have been inconsistent. A close examination of these studies revealed that these studies differed by timing of metformin exposure, population characteristics (cancer stage and histology), reference group, and adjustment for confounders. A study on small cell lung cancer reported improved survival³⁰, but the time window of metformin use was unclear. In a study of 750 Stage IV NSCLC patients based on the SEER-Medicare data, pre-diagnostic metformin use was associated with significantly improved overall survival, after adjustment for tumor characteristics and chemotherapy²⁸. However, in another study of lung cancer patients (NSCLC and small cell lung cancer were not differentiated), pre-diagnostic use of metformin increased risk of death after adjustment for age and tumor stage²⁶. Among studies that evaluated post-diagnostic metformin use^{25–27, 29, 31}, a recent retrospective cohort study reported a non-significant HR of 0.86 (95% CI, 0.68 to 1.09) for lung cancer-specific mortality³¹, after adjustment for multiple variables, although cancer stage was not adjusted and NSCLC and small cell lung cancer were not differentiated. A small clinical trial reported improved overall survival with metformin use compared to those on other anti-diabetic drugs among advanced stage NSCLC patients²⁷, while another small study found similar overall survival between patients with and without metformin use among locally advanced NSCLC patients²⁹. No adjustment was made for confounders in both studies^{27, 29}. Another report found borderline survival benefit associated with metformin mono-therapy after lung cancer diagnosis²⁵, but the survival was compared to non-diabetic patients rather than diabetics not on metformin, and tumor characteristics such as stage, grade or histology were not controlled in the multivariate analysis.

Compared to these studies, we were able to adjust for key confounders with available data on demographics, tumor characteristics, treatments, comorbidity, and other anti-diabetic medication use. Further, our study was based on the data from the MHS, an equal access system. Since use of medication and cancer outcomes are related to accessibility to medical care, including diabetes care and treatment, a study in an equal access system can minimize the potential effects of unequal access to health care and cancer outcome.

While post-diagnostic cumulative metformin use was associated with improved survival in our study, it is noteworthy that post-diagnostic users were younger, had less comorbidity and were more likely to be diagnosed at early stages, which may be related to better survival. However, these factors as well as baseline metformin, insulin and insulin secretagogues use were controlled for in the multivariate model and stratified analysis by tumor stage was conducted, suggesting that post-diagnostic cumulative metformin use was independently associated with improved survival. However, the residual confounding by these variables on survival outcome cannot be ruled out. In addition, we do not exclude the possible effects of

diabetes complications on the results if their distributions varied between the comparison groups.

Improved survival associated with metformin use is biologically plausible. Metformin activates AMPK-mTOR pathways and inhibits downstream cellular growth and proliferation in cancer cells^{23, 44}. The direct inhibition of cancer cell proliferation by metformin treatment has been demonstrated in *in vitro* studies of prostate and breast cancers^{23, 45, 46}. In lung cancer, research has shown that metformin could induce apoptosis and inhibit lung cancer cell growth *in vitro*⁷ and in xenograft models⁴⁷. In addition to the direct involvement in cellular process, metformin also indirectly contributes to anticancer actions by reducing insulin levels and improving insulin sensitivity⁵. Reductions in endogenous insulin levels have been shown to reduce tumor burden and growth⁴⁷.

The finding that the protective effect of post-diagnostic metformin use was only observed among those who also used metformin before cancer diagnosis suggests that the impact of metformin may appear only when it has been used for a certain length of period. However, this may also result from the possibility that patients with pre-diagnostic use discontinued the use after diagnosis due to more severe lung cancer, disease progression, or treatment complications, for which metformin is not recommended⁴⁸. Thus, longer duration of use could be the result of, rather than the cause of stable disease. For patients who used metformin only after lung cancer diagnosis, metformin use tended to have protective effects but the effects were not statistically significant probably because the duration of use might not be long enough to observe the significant effects. Furthermore, the protective effect of post-diagnostic metformin use was particularly significant among early-stage patients. The beneficial effects of metformin may be overwhelmed by disease severity among late stage patients.

While the survival benefit has molecular and biological relevance, there is a concern of healthy-user effect, in which metformin users may be at earlier stage of type II diabetes (because metformin is the first line treatment of type II diabetes) than non-users and thus may be healthier with better survival than non-users. However, in our study, there was higher percentage of insulin users among metformin users than metformin non-users (e.g. 23.75% vs. 8.31% at baseline, and 37.84% vs. 14.85% during follow up). As insulin is usually prescribed to patients with more advanced type II diabetes⁴⁹, the higher percentage of insulin users among metformin users in our study population suggested that metformin users in our study might not have a milder form of diabetes than non-users and thus the healthy-user effect might not be likely. Despite the fact that insulin use and advanced type II diabetes could increase mortality among cancer patients^{21, 22}, we still observed a reduced mortality among metformin users with prolonged duration of use.

It is noteworthy that there was an increase in mortality within 12 months of use and especially among early stage patients. It is not clear what factors might be related to the increased mortality in this group and further research is warranted.

Our study has the limitation of small numbers of subjects in stratified analysis. The unavailability of pharmacy data before year 2002 may have resulted in misclassification of

baseline exposure status (metformin use before cancer diagnosis). However, the baseline exposure in our study was only analyzed for effect modification but not for the main effect, which only involved use after lung cancer diagnosis. Similarly, due to the unavailability of MDR pharmacy data before 2002, misclassification in determining other anti-diabetic medications may have occurred. In addition, we do not exclude the possibility of residual confounding. For example, we used AJCC tumor stage, which is a general predictor of prognosis and does not contain more detailed information that may also affect prognosis (e.g. a single bone metastasis vs. metastases in multiple organs for stage IV tumors). Thus, residual confounding due to unmeasured tumor features might exist when overall tumor stage was used. Moreover, the length of follow up may not allow assessment of long-term use. However, the survival time is often short for lung cancer patients and thus lack of a long-term assessment due to a short follow-up time might be of less concern compared to cancers with long term survival. Finally, information in the current data was not sufficient to accurately estimate the cumulative doses, thus analysis by cumulative dose was not conducted.

In conclusion, among NSCLC diabetic patients in U.S. Military Health System, we observed survival benefit among patients with prolonged duration of metformin use and especially among early stage patients. Future research with a larger number of patients is warranted to confirm the findings.

References

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
2. Richardson LC, Pollack LA. Therapy insight: Influence of type 2 diabetes on the development, treatment and outcomes of cancer. *Nat Clin Pract Oncol*. 2005; 2:48–53. [PubMed: 16264856]
3. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer*. 2008; 8:915–28. [PubMed: 19029956]
4. Booth G, Cheng AY. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. *Methods Can J Diabetes*. 2013; 37(Suppl 1):S4–7. [PubMed: 24070961]
5. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. *Science*. 2005; 310:1642–6. [PubMed: 16308421]
6. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. Repositioning metformin for cancer prevention and treatment. *Trends Endocrinol Metab*. 2013; 24:469–80. [PubMed: 23773243]
7. Wu N, Gu C, Gu H, Hu H, Han Y, Li Q. Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153. *Neoplasia*. 2011; 58:482–90. [PubMed: 21895401]
8. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? *Mol Cancer Ther*. 2010; 9:1092–9. [PubMed: 20442309]
9. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. Metformin prevents tobacco carcinogen--induced lung tumorigenesis. *Cancer Prev Res (Phila)*. 2010; 3:1066–76. [PubMed: 20810672]
10. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. *PLoS One*. 2012; 7:e33411. [PubMed: 22448244]

11. Gandini S, Puntoni M, Heckman-Stoddard BM, Dunn BK, Ford L, DeCensi A, Szabo E. Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-analysis Taking into Account Biases and Confounders. *Cancer Prev Res (Phila)*. 2014; 7:867–85. [PubMed: 24985407]
12. Lega IC, Shah PS, Margel D, Beyene J, Rochon PA, Lipscombe LL. The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes. *Cancer Epidemiol Biomarkers Prev*. 2014; 23:1974–84. [PubMed: 25030683]
13. Bayraktar S, Hernandez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. *Cancer*. 2012; 118:1202–11. [PubMed: 21800293]
14. Lega IC, Austin PC, Gruneir A, Goodwin PJ, Rochon PA, Lipscombe LL. Association between metformin therapy and mortality after breast cancer: a population-based study. *Diabetes Care*. 2013; 36:3018–26. [PubMed: 23633525]
15. Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, Eng C, Hassan MM. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. *Br J Cancer*. 2012; 106:1374–8. [PubMed: 22421948]
16. Spillane S, Bennett K, Sharp L, Barron TI. A cohort study of metformin exposure and survival in patients with stage I–III colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2013; 22:1364–73. [PubMed: 23753040]
17. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, Fleshner N. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. *J Clin Oncol*. 2013; 31:3069–75. [PubMed: 23918942]
18. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig PA, Bae-Jump V. Metformin is associated with improved survival in endometrial cancer. *Gynecol Oncol*. 2014; 132:438–42. [PubMed: 24269517]
19. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. *Clin Cancer Res*. 2012; 18:2905–12. [PubMed: 22465831]
20. American Cancer Society. <http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer>
21. Tseng CH. Higher risk of mortality from lung cancer in Taiwanese people with diabetes. *Diabetes Res Clin Pract*. 2013; 102:193–201. [PubMed: 24262943]
22. Shieh SH, Probst JC, Sung FC, Tsai WC, Li YS, Chen CY. Decreased survival among lung cancer patients with co-morbid tuberculosis and diabetes. *BMC Cancer*. 2012; 12:174. [PubMed: 22578056]
23. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. *Cancer Res*. 2007; 67:10804–12. [PubMed: 18006825]
24. Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petrucci L, Birman E, Viollet B, Ferbeyre G, Pollak MN. Metformin reduces endogenous reactive oxygen species and associated DNA damage. *Cancer Prev Res (Phila)*. 2012; 5:536–43. [PubMed: 22262811]
25. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. *Diabetes Care*. 2012; 35:299–304. [PubMed: 22266734]
26. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain A, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. *BMC Cancer*. 2012; 12:410. [PubMed: 22978440]
27. Tan BX, Yao WX, Ge J, Peng XC, Du XB, Zhang R, Yao B, Xie K, Li LH, Dong H, Gao F, Zhao F, et al. Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes. *Cancer*. 2011; 117:5103–11. [PubMed: 21523768]
28. Lin JJ, Gallagher EJ, Sigel K, Mhango G, Galsky MD, Smith CB, LeRoith D, Wisnivesky JP. Survival of patients with stage IV lung cancer with diabetes treated with metformin. *Am J Respir Crit Care Med*. 2015; 191:448–54. [PubMed: 25522257]

29. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti SG, Aisner J, Zou W, Haffty BG, Jabbour SK. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. *J Thorac Dis.* 2015; 7:346–55. [PubMed: 25922712]
30. Kong F, Gao F, Liu H, Chen L, Zheng R, Yu J, Li X, Liu G, Jia Y. Metformin use improves the survival of diabetic combined small-cell lung cancer patients. *Tumour Biol.* 2015
31. Menamin UC, Cardwell CR, Hughes CM, Murray LM. Metformin use and survival from lung cancer: A population-based cohort study. *Lung Cancer.* 2016; 94:35–9. [PubMed: 26973204]
32. Hardman K, Hunt KJ, Carter RE, Jenkins C, Hill R, Lackland DT. Diabetes management and vaccination rates in the Southeast United States, 2000 through 2007. *Ethn Dis.* 2011; 21:13–9. [PubMed: 21462724]
33. Hazel-Fernandez L, Li Y, Nero D, Moretz C, Slabaugh L, Meah Y, Baltz J, Costantino M, Patel NC, Bouchard J. Racial/ethnic and gender differences in severity of diabetes-related complications, health care resource use, and costs in a Medicare population. *Popul Health Manag.* 2015; 18:115–22. [PubMed: 25290044]
34. Lin J, Carter CA, McGlynn KA, Zahm SH, Nations JA, Anderson WF, Shriver CD, Zhu K. A Prognostic Model to Predict Mortality among Non-Small-Cell Lung Cancer Patients in the U.S. Military Health System. *J Thorac Oncol.* 2015; 10:1694–702. [PubMed: 26473644]
35. Fritz, APC., Lack, A. International Classification of Diseases for Oncology. 3. Geneva: World Health Organization; 2000.
36. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM. Identifying persons with diabetes using Medicare claims data. *Am J Med Qual.* 1999; 14:270–7. [PubMed: 10624032]
37. Suissa S. Immortal time bias in pharmaco-epidemiology. *Am J Epidemiol.* 2008; 167:492–9. [PubMed: 18056625]
38. American Joint Committee on Cancer. *AJCC Cancer Staging Manual.* 7. New York, NY: Springer; 2010.
39. Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2013; 143:e278S–313S. [PubMed: 23649443]
40. Hsu CL, Chen KY, Shih JY, Ho CC, Yang CH, Yu CJ, Yang PC. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors. *BMC Cancer.* 2012; 12:241. [PubMed: 22695392]
41. Gill KS, Muntner P, Lafayette RA, Petersen J, Fink JC, Gilbertson DT, Bradbury BD. Red blood cell transfusion use in patients with chronic kidney disease. *Nephrol Dial Transplant.* 2013; 28:1504–15. [PubMed: 23389999]
42. Chen WW, Shao YY, Shau WY, Lin ZZ, Lu YS, Chen HM, Kuo RN, Cheng AL, Lai MS. The impact of diabetes mellitus on prognosis of early breast cancer in Asia. *Oncologist.* 2012; 17:485–91. [PubMed: 22467665]
43. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987; 40:373–83. [PubMed: 3558716]
44. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. *Endocr Rev.* 2009; 30:586–623. [PubMed: 19752219]
45. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Violette B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res.* 2007; 67:6745–52. [PubMed: 17638885]
46. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. *Proc Natl Acad Sci U S A.* 2013; 110:972–7. [PubMed: 23277563]
47. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. *Endocr Relat Cancer.* 2008; 15:833–9. [PubMed: 18469156]

48. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. *Ann Transl Med.* 2014; 2:57. [PubMed: 25333032]
49. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use. *Cleve Clin J Med.* 2011; 78:332–42. [PubMed: 21536829]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Impact Statement

This is a major lung cancer study that demonstrated the association between improved survival and prolonged duration of metformin use among diabetic patients after NSCLC diagnosis. The survival benefits were more evident in early stage patients.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1 Characteristics of non-small cell lung cancer patients by post-diagnostic metformin use in the Military Health System (2002–2007)

Variables	Total		No Use		Ever Use		P-Value
	N	%	N	%	N	%	
Age							0.016
<60	80	10.61	16	12.70	24	18.05	
60–69	237	34.75	53	42.06	53	39.85	
70–79	256	41.64	49	38.89	50	37.59	
80 and older	63	13.00	8	6.35	6	4.51	
Sex							0.100
Male	469	76.39	92	73.02	89	66.92	
Female	167	23.61	34	26.98	44	33.08	
Race							0.387
White	495	80.11	97	76.98	96	72.18	
Black	88	12.47	20	15.87	21	15.79	
Asian	32	3.98	7	5.56	10	7.52	
Other or Unknown	21	3.45	2	1.59	6	4.51	
Marital Status							0.493
Married	484	75.86	91	72.22	107	80.45	
Separated, Divorced or Widowed	122	19.89	28	22.22	19	14.29	
Other or Unknown	30	4.24	7	5.56	7	5.26	
Sponsor Service Branch							0.019
Army	242	36.34	52	41.27	53	39.85	
Navy	119	20.16	13	10.32	30	22.56	
Air Force	226	35.28	46	36.51	47	35.34	
Other or Unknown	49	8.22	15	11.90	3	2.26	
Tobacco Use							0.167
Never used	40	5.04	10	7.94	11	8.27	
Previous use	379	60.21	66	52.38	86	64.66	
Current use	180	27.85	44	34.92	31	23.31	

Variables	Total		No Use		Ever Use		P-Value
	N	%	N	%	N	%	
Unknown	37	26	6.90	6	4.76	5	3.76
Comorbidity Index Group							0.002
0	145	63	16.71	40	31.75	42	31.58
1	135	81	21.49	23	18.25	31	23.31
2 or more	336	233	61.80	63	50.00	60	45.11
Tumor Stage							<0.001
Stage I	213	108	28.65	37	39.37	68	51.13
Stage II	49	26	6.90	10	7.94	13	9.77
Stage III	161	101	26.79	31	24.60	29	21.80
Stage IV	190	127	33.69	43	34.13	20	15.04
Unknown	23	15	3.98	5	3.97	3	2.26
Histology							0.189
Squamous cell carcinoma	167	94	24.93	44	34.82	29	21.80
Adenocarcinoma	267	157	41.64	46	36.51	64	48.12
Large cell carcinoma	26	15	3.98	4	3.17	7	5.26
Other or Unknown	176	111	29.44	32	25.40	33	24.81
Baseline Metformin use[#]							<0.001
No	337	284	75.33	30	23.81	23	17.29
Yes	299	93	24.67	96	76.19	110	82.71
Baseline Insulin use[#]							0.183
No	537	321	85.15	100	79.37	116	87.22
Yes	99	56	14.85	26	20.63	17	12.78
Baseline Insulin secretagogues use[#]							<0.001
No	435	304	80.64	70	55.56	61	45.86
Yes	201	73	19.36	56	44.44	72	54.14
Baseline aspirin use[#]							<0.001
No	472	306	81.17	80	63.49	86	64.66
Yes	164	71	18.83	46	36.51	47	35.34

Baseline use means use before NSCL diagnosis

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 2
 Post-diagnostic cumulative metformin use in time-dependent multivariate Cox model for all-cause mortality

Variables	No.	HR#	95% CI
	Alive/Dead		
Metformin use *			
No use	104/273	1.00 (ref.)	1.00 (ref.)
Cumulative use (per one-year of use)	121/138	0.76	0.65 to 0.88
Age (yrs)	377/259	0.98	0.97 to 1.00
Sex			
Female	69/98	1.00 (ref.)	1.00 (ref.)
Male	156/313	1.12	0.87 to 1.45
Race			
White	162/333	1.00 (ref.)	1.00 (ref.)
Black	36/52	0.87	0.64 to 1.18
Asian	15/17	0.99	0.60 to 1.65
Other and Unknown	12/9	0.88	0.42 to 1.85
Tobacco use			
No use	19/21	1.00 (ref.)	1.00 (ref.)
Previous use	139/240	0.92	0.57 to 1.48
Current use	58/122	0.66	0.40 to 1.10
Unknown	9/28	1.51	0.84 to 2.73
Comorbidity index group			
0	54/91	1.00 (ref.)	1.00 (ref.)
1	57/78	0.78	0.56 to 1.08
2 or more	114/242	0.82	0.63 to 1.08
Tumor Stage			
I	126/87	1.00 (ref.)	1.00 (ref.)
II	24/25	1.13	0.69 to 1.83
III	42/119	1.80	1.27 to 2.54
IV	25/165	2.03	1.44 to 2.86
Unknown	8/15	1.26	0.69 to 2.30

Variables	No. Alive/Dead	HR#	95% CI
Histology			
Squamous cell carcinoma	55/112	1.00 (ref.)	1.00 (ref.)
Adenocarcinoma	113/154	1.15	0.88 to 1.52
Large cell carcinoma	10/16	0.83	0.45 to 1.51
Other	47/129	1.09	0.83 to 1.43
Surgery			
No	54/287	1.00 (ref.)	1.00 (ref.)
Yes	171/124	0.45	0.34 to 0.59
Chemotherapy			
No	110/197	1.00 (ref.)	1.00 (ref.)
Yes	113/208	0.49	0.38 to 0.62
Unknown	2/6	1.20	0.53 to 2.75
Radiation			
No	137/173	1.00 (ref.)	1.00 (ref.)
Yes	87/237	1.14	0.91 to 1.43
Unknown	1/1	4.41	0.58 to 33.38
Baseline metformin use			
No	113/224	1.00 (ref.)	1.00 (ref.)
Yes	112/187	1.24	0.94 to 1.63
Baseline insulin use			
No	190/347	1.00 (ref.)	1.00 (ref.)
Yes	35/64	1.12	0.76 to 1.67
Baseline insulin secretagogues use			
No	155/280	1.00 (ref.)	1.00 (ref.)
Yes	70/131	1.45	1.12 to 1.88
Baseline aspirin use			
No	162/310	1.00 (ref.)	1.00 (ref.)
Yes	63/101	0.95	0.67 to 1.33
Years in cohort (yrs)	377/259	0.29	0.25 to 0.33

* Modeled as a time-dependent variable; The unit modeled is the effect of use per year.

Adjusted for all variables shown in table.
HR=Hazard Ratio; CI=Confidence Interval

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Hazard ratios of post-diagnostic cumulative use of metformin groups in time-dependent Cox model for all-cause mortality

Table 3

Cumulative use groups*	No. (Alive/Dead)	HR#	95% CI
No use	104/273	1.00 (ref.)	1.00 (ref.)
>0 to 12 months	24/102	2.05	1.51 to 2.78
>12 to 24 months	19/27	0.95	0.59 to 1.53
>24 months	78/9	0.19	0.09 to 0.40

* Modeled as a time-dependent variable

Adjusted for the same variables in Table 2, including age, sex, race, tobacco use, comorbidity index, tumor stage, histology, surgery, chemotherapy, radiation therapy, baseline metformin use, baseline insulin use, baseline insulin secretagogues use, baseline aspirin use

HR=Hazard Ratio; CI=Confidence Interval

Post-diagnostic cumulative use of metformin for all-cause mortality in time-dependent Cox model, stratified by baseline metformin use before cancer diagnosis

Table 4

Variables	Metformin use before diagnosis: Yes			Metformin use before diagnosis: No		
	No. (Alive/Dead)	HR#	95% CI	No. (Alive/Dead)	HR#	95% CI
Cumulative use*						
No use	23/70	1.00 (ref.)	1.00 (ref.)	81/203	1.00 (ref.)	1.00 (ref.)
Cumulative use (per one year of use)	89/117	0.68	0.57 to 0.82	32/21	0.99	0.78 to 1.25
Cumulative use group*						
No use	23/70	1.00 (ref.)	1.00 (ref.)	81/203	1.00 (ref.)	1.00 (ref.)
>0 to 12 months	12/84	1.70	1.18 to 2.45	12/18	1.84	0.99 to 3.40
>12 to 24 months	16/25	0.75	0.43 to 1.31	3/2	0.96	0.24 to 3.91
>24 months	61/8	0.13	0.06 to 0.29	17/1	0.80	0.31 to 2.10

* Modeled as a time-dependent variable

Adjusted for all variables shown in Table 2 except the stratifying variable

HR=Hazard Ratio; CI=Confidence Interval

Post-diagnostic cumulative use of metformin for all-cause mortality in time-dependent Cox model, stratified by cancer stage group

Table 5

Variables	Early Stage (stages I and II)			Late Stage (stages III and IV)		
	No. (Alive/Dead)	HR#	95% CI	No. (Alive/Dead)	HR#	95% CI
Cumulative use*						
No use	69/65	1.00 (ref.)	1.00 (ref.)	31/197	1.00 (ref.)	1.00 (ref.)
Cumulative use (per one-year of use)	81/47	0.84	0.66 to 1.06	36/87	0.92	0.78 to 1.10
Cumulative use group*						
No use	69/65	1.00 (ref.)	1.00 (ref.)	31/197	1.00 (ref.)	1.00 (ref.)
>0 to 12 months	16/31	4.09	2.32 to 7.19	7/67	1.34	0.90 to 1.99
>12 to 24 months	12/11	1.93	0.85 to 4.39	6/16	0.88	0.50 to 1.53
>24 months	53/5	0.26	0.09 to 0.73	23/4	0.75	0.43 to 1.31

* Modeled as a time-dependent variable

Adjusted for all variables shown in Table 2 except the stratifying variable

HR=Hazard Ratio; CI=Confidence Interval